Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Medtronic
Harvard Business School
Merck
Mallinckrodt

Last Updated: May 27, 2022

Sarecycline hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for sarecycline hydrochloride and what is the scope of patent protection?

Sarecycline hydrochloride is the generic ingredient in one branded drug marketed by Almirall and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sarecycline hydrochloride has sixty-seven patent family members in twenty countries.

One supplier is listed for this compound.

Summary for sarecycline hydrochloride
International Patents:67
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 5
Patent Applications: 1
What excipients (inactive ingredients) are in sarecycline hydrochloride?sarecycline hydrochloride excipients list
DailyMed Link:sarecycline hydrochloride at DailyMed
Recent Clinical Trials for sarecycline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Derm Research, PLLCPhase 4
Sadick Research GroupPhase 3
AllerganPhase 3

See all sarecycline hydrochloride clinical trials

Pharmacology for sarecycline hydrochloride

US Patents and Regulatory Information for sarecycline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for sarecycline hydrochloride

Country Patent Number Title Estimated Expiration
Spain 2463457 See Plans and Pricing
Japan 2015205939 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体 (TETRACYCLINE DERIVATIVE FOR TREATMENT OF BACTERIA INFECTION, VIRUS INFECTION AND PARASITE INFECTION) See Plans and Pricing
Spain 2548261 See Plans and Pricing
Poland 2120963 See Plans and Pricing
Japan 2010513527 See Plans and Pricing
European Patent Office 3045449 DÉRIVÉS DE LA TÉTRACYCLINE POUR LE TRAITEMENT D'INFECTIONS BACTERIELLES, VIRALES ET PARASITAIRES (TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS) See Plans and Pricing
Cyprus 1121135 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Boehringer Ingelheim
Medtronic
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.